RJFSA
VIRX

Raymond James Financial Services Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,904
Closed -$42K – 2918
2020
Q1 		$42K Buy
+2,904
New +$63K ﹤0.01% 2329

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Raymond James Financial Services Advisors's VIRX Position: Q2 2020 in Review

Raymond James Financial Services Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2020, closing a stake of 2,904 shares — an estimated $42K sold.

Raymond James Financial Services Advisors first reported a position in VIRX in Q1 2020 and held it in 1 quarter. The position peaked at $42K in Q1 2020. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2020.

  • Raymond James Financial Services Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 2,904 Viracta Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $42K.
  • Raymond James Financial Services Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $42K in Q1 2020.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2020, filed 17 Jul 2020.